Sodium-glucose cotransporter 2 (SGLT2) inhibitors reportedly not only improve hyperglycemia but also suppress the onset of cardiovascular diseases and prevent renal dysfunction in patients with type 2 diabetes [1–5], including in Asian patients, whose body mass index (BMI) and estimated glomerular filtration rate (eGFR) are generally smaller than in Western people [6,7]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.